Tirzepatide is an agonist of the receptors of two insulin sensitizing polypeptides, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide 1), that is used as therapy of type 2 diabetes, obstructive sleep apnea, and obesity. Tirzepatide has been linked to minimal instances of elevations in serum aminotransferase levels during therapy and rare episodes of clinically apparent liver injury.